Overview of Targeted Drugs for Mature B-Cell Non-hodgkin Lymphomas

Immune checkpoint blockade and its combination therapy with small-molecule inhibitors for cancer treatment

(2019) Wang Manni et al.   BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER

Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: a phase 1/2a study

(2019) Anas Younes et al.   Lancet Haematology

Targeting the Bcl-2 Family in B Cell Lymphoma

(2019) Clare M. Adams et al.   Frontiers in Oncology

Tolerability and activity of ublituximab, umbralisib, and ibrutinib in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: a phase 1 dose escalation and expansion trial

(2019) Loretta J Nastoupil et al.   Lancet Haematology

Choosing the right pharmacotherapy for non-Hodgkin’s lymphoma: does one size fit all?

(2019) Taha Al Juhaishi et al.   EXPERT OPINION ON PHARMACOTHERAPY

Novel targeted therapeutic agents for the treatment of childhood, adolescent and young adult non-Hodgkin lymphoma

(2019) Matthew J. Barth et al.   BRITISH JOURNAL OF HAEMATOLOGY

CD47/SIRPα blocking enhances CD19/CD3-bispecific T cell engager antibody-mediated lysis of B cell malignancies

(2019) Lijun Xu et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Toxicities of CD19 CAR-T cell immunotherapy

(2019) Alexandre V. Hirayama et al.   AMERICAN JOURNAL OF HEMATOLOGY

How I manage patients with relapsed/refractory diffuse large B cell lymphoma

(2018) Christian Gisselbrecht et al.   BRITISH JOURNAL OF HAEMATOLOGY

Bispecific antibodies in haematological malignancies

(2018) Andreas Viardot et al.   CANCER TREATMENT REVIEWS

Strategic Therapeutic Targeting to Overcome Venetoclax Resistance in Aggressive B-cell Lymphomas

(2018) Lan V. Pham et al.   CLINICAL CANCER RESEARCH

CAR T cell immunotherapy in hematology and beyond

(2018) Claudia Rossig   CLINICAL IMMUNOLOGY

How to Approach a Hodgkin Lymphoma Patient With Relapse After Autologous SCT: Allogeneic SCT

(2018) Matthew Mei et al.   Clinical Lymphoma Myeloma & Leukemia

CD19 CAR-T cell therapy for relapsed/refractory acute lymphoblastic leukemia: factors affecting toxicities and long-term efficacies

(2018) Li-Na Zhang et al.   Journal of Hematology & Oncology

Venetoclax–Rituximab in Chronic Lymphocytic Leukemia

(2018)   NEW ENGLAND JOURNAL OF MEDICINE

Venetoclax–Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia

(2018) John F. Seymour et al.   NEW ENGLAND JOURNAL OF MEDICINE

Current status and future directions of cancer immunotherapy

(2018) Hongming Zhang et al.   Journal of Cancer

Immune Checkpoint Inhibitors to Treat Malignant Lymphomas

(2018) Magdalena Witkowska et al.   Journal of Immunology Research

Ibrutinib, lenalidomide, and rituximab in relapsed or refractory mantle cell lymphoma (PHILEMON): a multicentre, open-label, single-arm, phase 2 trial

(2018) Mats Jerkeman et al.   Lancet Haematology

The promise of CAR T-cell therapy in aggressive B-cell lymphoma

(2018) Ranjit Nair et al.   BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY

Pembrolizumab for the first-line treatment of non-small cell lung cancer

(2018) Kiichiro Ninomiya et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Phase I/II clinical trial of ibrutinib and buparlisib in relapsed/refractory diffuse large B-cell lymphoma, mantle cell lymphoma, and follicular lymphoma.

(2018) Connie Lee Batlevi et al.   JOURNAL OF CLINICAL ONCOLOGY

Brentuximab vedotin in Hodgkin lymphoma and anaplastic large-cell lymphoma: an evidence-based review

(2018) Eva Maria Donato et al.   OncoTargets and Therapy

Copanlisib for treatment of B-cell malignancies: the development of a PI3K inhibitor with considerable differences to idelalisib

(2018) Günter Krause et al.   Drug Design Development and Therapy

Small-Molecule Inhibitors for the Treatment of Diffuse Large B Cell Lymphoma

(2018) Joanna Rhodes et al.   Current Hematologic Malignancy Reports

Recent advances in CAR T-cell toxicity: Mechanisms, manifestations and management

(2018) Jennifer N. Brudno et al.   BLOOD REVIEWS

Novel therapeutic agents for relapsed classical Hodgkin lymphoma

(2018) Gottfried Keudell et al.   BRITISH JOURNAL OF HAEMATOLOGY

Optimal Management of Adverse Events From Copanlisib in the Treatment of Patients With Non-Hodgkin Lymphomas

(2018) Bruce D. Cheson et al.   Clinical Lymphoma Myeloma & Leukemia

Fixed Duration of Venetoclax-Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia Eradicates Minimal Residual Disease and Prolongs Survival: Post-Treatment Follow-Up of the MURANO Phase III Study

(2018) Arnon P. Kater et al.   JOURNAL OF CLINICAL ONCOLOGY

Clinical prognostic scores are poor predictors of overall survival in various types of malignant lymphomas

(2018) Jorne Lionel Biccler et al.   LEUKEMIA & LYMPHOMA

Checkpoint Inhibitors Hodgkin Lymphoma and Non-Hodgkin Lymphoma

(2018) Bei Hu et al.   Current Hematologic Malignancy Reports

Combining Biology and Chemistry for a New Take on Chemotherapy: Antibody-Drug Conjugates in Hematologic Malignancies

(2018) Helen Ma et al.   Current Hematologic Malignancy Reports

Chimeric antigen receptor (CAR) T therapies for the treatment of hematologic malignancies: clinical perspective and significance

(2018) Michael M. Boyiadzis et al.   Journal for ImmunoTherapy of Cancer

Checkpoint-modulating immunotherapies in tumor treatment: Targets, drugs, and mechanisms

(2018) Lu Sun et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

Pan-phosphatidylinositol 3-kinase inhibition with buparlisib in patients with relapsed or refractory non-Hodgkin lymphoma

(2017) Anas Younes et al.   HAEMATOLOGICA

CUDC-907 in relapsed/refractory diffuse large B-cell lymphoma, including patients with MYC-alterations: results from an expanded phase I trial

(2017) Yasuhiro Oki et al.   HAEMATOLOGICA

SAFETY AND CLINICAL ACTIVITY OF TEMSIROLIMUS IN COMBINATION WITH RITUXIMAB AND DHAP IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA-REPORT OF THE PROSPECTIVE, MULTICENTER PHASE II STORM TRIAL

(2017) M. Witzens-Harig et al.   HEMATOLOGICAL ONCOLOGY

Phosphatidylinositol 3-Kinase Inhibition by Copanlisib in Relapsed or Refractory Indolent Lymphoma

(2017) Martin Dreyling et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma

(2017) Matthew S. Davids et al.   JOURNAL OF CLINICAL ONCOLOGY

Observational study of lenalidomide in patients with mantle cell lymphoma who relapsed/progressed after or were refractory/intolerant to ibrutinib (MCL-004)

(2017) Michael Wang et al.   Journal of Hematology & Oncology

Syk inhibitors in clinical development for hematological malignancies

(2017) Delong Liu et al.   Journal of Hematology & Oncology

Lymphoma classification update: B-cell non-Hodgkin lymphomas

(2017) Manli Jiang et al.   Expert Review of Hematology

Dual SYK/JAK inhibition overcomes ibrutinib resistance in chronic lymphocytic leukemia: Cerdulatinib, but not ibrutinib, induces apoptosis of tumor cells protected by the microenvironment

(2017) Ailin Guo et al.   Oncotarget

An Update on the Use of Immunotherapy in the Treatment of Lymphoma

(2017) Thomas U. Marron et al.   Current Hematologic Malignancy Reports

Small Molecule Inhibitors in Chronic Lymphocytic Lymphoma and B Cell Non-Hodgkin Lymphoma

(2017) Allison Rosenthal   Current Hematologic Malignancy Reports

Pan-phosphatidylinositol 3-kinase inhibition with buparlisib in patients with relapsed or refractory non-Hodgkin lymphoma

(2017) Anas Younes et al.   HAEMATOLOGICA

CUDC-907 in relapsed/refractory diffuse large B-cell lymphoma, including patients with MYC-alterations: results from an expanded phase I trial

(2017) Yasuhiro Oki et al.   HAEMATOLOGICA

Proteasome inhibitor-induced gastrointestinal toxicity

(2017) Romany L. Stansborough et al.   Current Opinion in Supportive and Palliative Care

PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome

(2017) Hashem O. Alsaab et al.   Frontiers in Pharmacology

Therapeutic Antibodies: What Have We Learnt from Targeting CD20 and Where Are We Going?

(2017) Michael J. E. Marshall et al.   Frontiers in Immunology

The role of novel immunotherapies in non-Hodgkin lymphoma

(2017) Allyson Pishko et al.   Translational Cancer Research

Molecular mechanism of PD-1/PD-L1 blockade via anti-PD-L1 antibodies atezolizumab and durvalumab

(2017) Hyun Tae Lee et al.   Scientific Reports

Idelalisib for treatment of B-cell malignancies

(2016) B. Do et al.   AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY

Therapeutic Potential of T Cell Chimeric Antigen Receptors (CARs) in Cancer Treatment: Counteracting Off-Tumor Toxicities for Safe CAR T Cell Therapy

(2016) Gideon Gross et al.   Annual Review of Pharmacology and Toxicology

Discovery of TAK-659 an orally available investigational inhibitor of Spleen Tyrosine Kinase (SYK)

(2016) Betty Lam et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed/refractory diffuse large B-cell lymphoma

(2016) A. Viardot et al.   BLOOD

Toxicities of chimeric antigen receptor T cells: recognition and management

(2016) Jennifer N. Brudno et al.   BLOOD

The 2016 revision of the World Health Organization classification of lymphoid neoplasms

(2016) S. H. Swerdlow et al.   BLOOD

The Dual Syk/JAK Inhibitor Cerdulatinib Antagonizes B-cell Receptor and Microenvironmental Signaling in Chronic Lymphocytic Leukemia

(2016) Matthew D. Blunt et al.   CLINICAL CANCER RESEARCH

Targeting BCL2 With BH3 Mimetics: Basic Science and Clinical Application of Venetoclax in Chronic Lymphocytic Leukemia and Related B Cell Malignancies

(2016) AW Roberts et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Checkpoint Inhibitors and Other Immune Therapies for Hodgkin and Non-Hodgkin Lymphoma

(2016) Eri Matsuki et al.   CURRENT TREATMENT OPTIONS IN ONCOLOGY

The Emerging Role of PI3K Inhibitors in the Treatment of Hematological Malignancies: Preclinical Data and Clinical Progress to Date

(2016) Till Seiler et al.   DRUGS

Polatuzumab vedotin. Anti-CD79b antibody-drug conjugate, Treatment of hematologic malignancies

(2016)   DRUGS OF THE FUTURE

A phase II trial to evaluate the efficacy of fostamatinib in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL)

(2016) Ian W. Flinn et al.   EUROPEAN JOURNAL OF CANCER

Alemtuzumab consolidation in chronic lymphocytic leukaemia: a phase I/II multicentre trial

(2016) Othman Al-Sawaf et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Idelalisib for the treatment of non-Hodgkin lymphoma

(2016) Solomon A. Graf et al.   EXPERT OPINION ON PHARMACOTHERAPY

Efficacy and safety of idelalisib in patients with relapsed, rituximab- and alkylating agent-refractory follicular lymphoma: a subgroup analysis of a phase 2 study

(2016) Gilles Salles et al.   HAEMATOLOGICA

Phase I study of single-agent CC-292, a highly selective Brutons tyrosine kinase inhibitor, in relapsed/refractory chronic lymphocytic leukemia

(2016) J. R. Brown et al.   HAEMATOLOGICA

Evaluation of the diagnostic and prognostic value of PDL1 expression in Hodgkin and B-cell lymphomas

(2016) Thomas Menter et al.   HUMAN PATHOLOGY

Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study

(2016) Alexander M. Lesokhin et al.   JOURNAL OF CLINICAL ONCOLOGY

Bispecific T-Cell Engager (BiTE) Antibody Construct Blinatumomab for the Treatment of Patients With Relapsed/Refractory Non-Hodgkin Lymphoma: Final Results From a Phase I Study

(2016) Maria-Elisabeth Goebeler et al.   JOURNAL OF CLINICAL ONCOLOGY

PRT062607 Achieves Complete Inhibition of the Spleen Tyrosine Kinase at Tolerated Exposures Following Oral Dosing in Healthy Volunteers

(2016) Greg Coffey et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, dose-escalation, phase 1 trial

(2016) Anas Younes et al.   LANCET ONCOLOGY

Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma: a single-centre, open-label, phase 2 trial

(2016) Michael L Wang et al.   LANCET ONCOLOGY

Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial

(2016) Anas Younes et al.   LANCET ONCOLOGY

ADCT-301, a Pyrrolobenzodiazepine (PBD) Dimer-Containing Antibody-Drug Conjugate (ADC) Targeting CD25-Expressing Hematological Malignancies

(2016) M. J. Flynn et al.   MOLECULAR CANCER THERAPEUTICS

Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia

(2016) Andrew W. Roberts et al.   NEW ENGLAND JOURNAL OF MEDICINE

Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia

(2016) John C. Byrd et al.   NEW ENGLAND JOURNAL OF MEDICINE

Targeting anti-apoptotic Bcl2 proteins with scyllatoxin-based BH3 domain mimetics

(2016) M. Margaret Harris et al.   ORGANIC & BIOMOLECULAR CHEMISTRY

Fabrication of Bacteria Environment Cubes with Dry Lift-Off Fabrication Process for Enhanced Nitrification

(2016) S. A. P. L. Samarasinghe et al.   PLoS One

Mature aggressive B-cell lymphoma across age groups – molecular advances and therapeutic implications

(2016) Jonas Lange et al.   Expert Review of Hematology

New targeted therapies for malignant lymphoma based on molecular heterogeneity

(2016) Heike Horn et al.   Expert Review of Hematology

Immune checkpoint inhibitors in Hodgkin and non-Hodgkin lymphoma: how they work and when to use them

(2016) Kerry J. Savage et al.   Expert Review of Hematology

Targeting the PD-1 pathway in patients with relapsed classic Hodgkin lymphoma following allogeneic stem cell transplant is safe and effective

(2016) Jose Caetano Villasboas et al.   Oncotarget

CD30 and CD30-Targeted Therapies in Hodgkin Lymphoma and Other B cell Lymphomas

(2016) Geetika Bhatt et al.   Current Hematologic Malignancy Reports

Efficacy and safety of idelalisib in patients with relapsed, rituximab- and alkylating agent-refractory follicular lymphoma: a subgroup analysis of a phase 2 study

(2016) Gilles Salles et al.   HAEMATOLOGICA

Phase I study of single-agent CC-292, a highly selective Brutons tyrosine kinase inhibitor, in relapsed/refractory chronic lymphocytic leukemia

(2016) J. R. Brown et al.   HAEMATOLOGICA

mTOR inhibition in diffuse large B-cell lymphoma: new hope?

(2016) Georg Hess   Lancet Haematology

Safety and activity of BTK inhibitor ibrutinib combined with ofatumumab in chronic lymphocytic leukemia: a phase 1b/2 study

(2015) S. M. Jaglowski et al.   BLOOD

A phase 1 clinical trial of the selective BTK inhibitor ONO/GS-4059 in relapsed and refractory mature B-cell malignancies

(2015) H. S. Walter et al.   BLOOD

FDA Approval: Idelalisib Monotherapy for the Treatment of Patients with Follicular Lymphoma and Small Lymphocytic Lymphoma

(2015) B. W. Miller et al.   CLINICAL CANCER RESEARCH

Bispecific antibodies

(2015) Roland E. Kontermann et al.   DRUG DISCOVERY TODAY

Blinatumomab for the treatment of acute lymphoblastic leukemia

(2015) Jason B. Kaplan et al.   INVESTIGATIONAL NEW DRUGS

Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial

(2015) Robert J. Motzer et al.   JOURNAL OF CLINICAL ONCOLOGY

ABT-199 (venetoclax) and BCL-2 inhibitors in clinical development

(2015) Shundong Cang et al.   Journal of Hematology & Oncology

Bispecific antibodies and their applications

(2015) Gaowei Fan et al.   Journal of Hematology & Oncology

Histone Deacetylase Inhibitors in Clinical Studies as Templates for New Anticancer Agents

(2015) Madhusoodanan Mottamal et al.   MOLECULES

Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer

(2015) Edward B. Garon et al.   NEW ENGLAND JOURNAL OF MEDICINE

PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma

(2015) Stephen M. Ansell et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cerdulatinib, a novel dual SYK/JAK kinase inhibitor, has broad anti-tumor activity in both ABC and GCB types of diffuse large B cell lymphoma

(2015) Jiao Ma et al.   Oncotarget

A multicentre phase II study of vorinostat in patients with relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma

(2014) Michinori Ogura et al.   BRITISH JOURNAL OF HAEMATOLOGY

Phase I/II trial of vorinostat with rituximab, cyclophosphamide, etoposide and prednisone as palliative treatment for elderly patients with relapsed or refractory diffuse large B-cell lymphoma not eligible for autologous stem cell transplantation

(2014) David J. Straus et al.   BRITISH JOURNAL OF HAEMATOLOGY

Bispecific antibody platforms for cancer immunotherapy

(2014) Roeland Lameris et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Emerging therapies targeting the ubiquitin proteasome system in cancer

(2014) Nathaniel M. Weathington et al.   JOURNAL OF CLINICAL INVESTIGATION

Discovery of GS-9973, a Selective and Orally Efficacious Inhibitor of Spleen Tyrosine Kinase

(2014) Kevin S. Currie et al.   JOURNAL OF MEDICINAL CHEMISTRY

Idelalisib: targeting PI3Kδ in B-cell malignancies

(2014) Judith A Gilbert   LANCET ONCOLOGY

Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study

(2014) Jan A Burger et al.   LANCET ONCOLOGY

Phase 1/2 Study of Ocaratuzumab, an Fc-Engineered Humanized Anti-CD20 Monoclonal Antibody, in Low-Affinity FcγRIIIa Patients with Previously Treated Follicular Lymphoma

(2014) Kristen N. Ganjoo et al.   LEUKEMIA & LYMPHOMA

PI3Kδ Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma

(2014) Ajay K. Gopal et al.   NEW ENGLAND JOURNAL OF MEDICINE

Strategies for the management of adverse events associated with mTOR inhibitors

(2014) Bruce Kaplan et al.   Transplantation Reviews

CD30 targeting with brentuximab vedotin: a novel therapeutic approach to primary effusion lymphoma

(2013) S. Bhatt et al.   BLOOD

A phase I/II trial to evaluate the safety, feasibility and activity of salvage therapy consisting of the mTOR inhibitor Temsirolimus added to standard therapy of Rituximab and DHAP for the treatment of patients with relapsed or refractory diffuse large cell B-Cell lymphoma – the STORM trial

(2013) Mathias Witzens-Harig et al.   BMC CANCER

Targeting the ubiquitin–proteasome system for cancer therapy

(2013) Min Shen et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

Disabling Immune Tolerance by Programmed Death-1 Blockade With Pidilizumab After Autologous Hematopoietic Stem-Cell Transplantation for Diffuse Large B-Cell Lymphoma: Results of an International Phase II Trial

(2013) Philippe Armand et al.   JOURNAL OF CLINICAL ONCOLOGY

Ibrutinib and novel BTK inhibitors in clinical development

(2013) Akintunde Akinleye et al.   Journal of Hematology & Oncology

Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial

(2013) Jason R Westin et al.   LANCET ONCOLOGY

Fostamatinib inhibits B-cell receptor signaling, cellular activation and tumor proliferation in patients with relapsed and refractory chronic lymphocytic leukemia

(2013) S E M Herman et al.   LEUKEMIA

Combination of rituximab and mammalian target of rapamycin inhibitor everolimus (RAD001) in diffuse large B-cell lymphoma

(2013) Zi-Zhen Xu et al.   LEUKEMIA & LYMPHOMA

Ofatumumab monotherapy in rituximab-refractory follicular lymphoma: results from a multicenter study

(2012) M. S. Czuczman et al.   BLOOD

Adverse events associated with mTOR inhibitors

(2012) Nicolas Pallet et al.   Expert Opinion On Drug Safety

Everolimus in combination with rituximab induces complete responses in heavily pretreated diffuse large B-cell lymphoma

(2012) J. A. Barnes et al.   HAEMATOLOGICA

Alemtuzumab in Combination With Methylprednisolone Is a Highly Effective Induction Regimen for Patients With Chronic Lymphocytic Leukemia and Deletion of TP53: Final Results of the National Cancer Research Institute CLL206 Trial

(2012) Andrew R. Pettitt et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase I study of the anti-CD40 humanized monoclonal antibody lucatumumab (HCD122) in relapsed chronic lymphocytic leukemia

(2012) John C. Byrd et al.   LEUKEMIA & LYMPHOMA

DARTs take aim at BiTEs

(2011) C. Rader   BLOOD

Application of dual affinity retargeting molecules to achieve optimal redirected T-cell killing of B-cell lymphoma

(2011) P. A. Moore et al.   BLOOD

Antitumor Activity of the Investigational Proteasome Inhibitor MLN9708 in Mouse Models of B-cell and Plasma Cell Malignancies

(2011) E. C. Lee et al.   CLINICAL CANCER RESEARCH

Second Generation Proteasome Inhibitors: Carfilzomib and Immunoproteasome-Specific Inhibitors (IPSIs)

(2011) D. J. Kuhn et al.   CURRENT CANCER DRUG TARGETS

Mammalian Target of Rapamycin (mTOR) Inhibitors

(2011) Sofia Sofroniadou et al.   DRUG SAFETY

Mocetinostat (MGCD0103): a review of an isotype-specific histone deacetylase inhibitor

(2011) Yanis Boumber et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Mocetinostat for relapsed classical Hodgkin's lymphoma: an open-label, single-arm, phase 2 trial

(2011) Anas Younes et al.   LANCET ONCOLOGY

A Phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma

(2010) Patrick B. Johnston et al.   AMERICAN JOURNAL OF HEMATOLOGY

The treatment of recurrent/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL) with everolimus results in clinical responses and mobilization of CLL cells into the circulation

(2010) Clive S. Zent et al.   CANCER

Evaluation of the Proteasome Inhibitor MLN9708 in Preclinical Models of Human Cancer

(2010) E. Kupperman et al.   CANCER RESEARCH

Effector Cell Recruitment with Novel Fv-based Dual-affinity Re-targeting Protein Leads to Potent Tumor Cytolysis and in Vivo B-cell Depletion

(2010) Syd Johnson et al.   JOURNAL OF MOLECULAR BIOLOGY

Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial

(2010) M Hallek et al.   LANCET

FDA Approval Summary: Temsirolimus as Treatment for Advanced Renal Cell Carcinoma

(2010) V. E. Kwitkowski et al.   ONCOLOGIST

Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia

(2009) J. W. Friedberg et al.   BLOOD

Phase I Study of Ipilimumab, an Anti-CTLA-4 Monoclonal Antibody, in Patients with Relapsed and Refractory B-Cell Non-Hodgkin Lymphoma

(2009) S. M. Ansell et al.   CLINICAL CANCER RESEARCH

Clinical Studies of Histone Deacetylase Inhibitors

(2009) H. M. Prince et al.   CLINICAL CANCER RESEARCH

A phase II study of bortezomib in patients with MALT lymphoma

(2009) M. Troch et al.   HAEMATOLOGICA

Phase I Study of the Humanized Anti-CD40 Monoclonal Antibody Dacetuzumab in Refractory or Recurrent Non-Hodgkin's Lymphoma

(2009) Ranjana Advani et al.   JOURNAL OF CLINICAL ONCOLOGY

The future of small molecule inhibitors in lymphoma

(2009) John Gerecitano   Current Oncology Reports

Targeting Bcl-2 family proteins modulates the sensitivity of B-cell lymphoma to rituximab-induced apoptosis

(2008) C. Stolz et al.   BLOOD

Targeting Bcl-2 family members with the BH3 mimetic AT-101 markedly enhances the therapeutic effects of chemotherapeutic agents in in vitro and in vivo models of B-cell lymphoma

(2008) L. Paoluzzi et al.   BLOOD

Potent In vitro and In vivo Activity of an Fc-Engineered Anti-CD19 Monoclonal Antibody against Lymphoma and Leukemia

(2008) H. M. Horton et al.   CANCER RESEARCH

Targeting the ubiquitin-proteasome system for cancer therapy

(2008) Yili Yang et al.   CANCER SCIENCE